CHPA Weighs In As Prop 65 Amicus Brief Filed In Calif. Supreme Court
This article was originally published in The Tan Sheet
Executive Summary
The Consumer Healthcare Products Association's amicus curiae brief in defense of nicotine-replacement therapy manufacturers involved in California Prop 65 litigation reflects the group's concern the labeling conflict involved could extend to other OTC drugs
You may also be interested in...
German Firm Hopes To Drill Into U.S. Market With Anti-Dandruff Ingredient
Ichthyol-Gesellschaft is looking to introduce sodium shale oil sulfonate into FDA's OTC monograph so the ingredient can be generally recognized as safe and effective as a treatment for dandruff
German Firm Hopes To Drill Into U.S. Market With Anti-Dandruff Ingredient
Ichthyol-Gesellschaft is looking to introduce sodium shale oil sulfonate into FDA's OTC monograph so the ingredient can be generally recognized as safe and effective as a treatment for dandruff
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT firms' reliance on "unpublished, ad hoc" FDA statements to support their contention that a Proposition 65 warning on OTC smoking cessation products conflicts with federal law is improper, according to a brief filed in California Supreme Court April 15